Aadi reports third quarter 2021 financial results and provides business update

Los angeles, nov. 10, 2021 (globe newswire) -- aadi bioscience, inc. (“aadi”) (nasdaq: aadi), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today reported financial results for the three and nine months ended september 30, 2021 and provided a general business update.

AADI Ratings Summary

AADI Quant Ranking